Pharming Group N.V. ADS, each representing 10 ordinary shares (PHAR) is a publicly traded Healthcare sector company. As of May 21, 2026, PHAR trades at $12.95 with a market cap of $891.29M and a P/E ratio of 0.00. PHAR moved +0.00% today. Year to date, PHAR is -23.44%; over the trailing twelve months it is +28.70%. Its 52-week range spans $7.31 to $21.34. Analyst consensus is strong buy with an average price target of $38.00. Rallies surfaces PHAR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Pharming Group Logs 27% Revenue Growth and $26M Profit in 2025: Pharming Group’s total revenues climbed 27% in 2025, with operating profit swinging to $26 million from a prior-year loss and operating cash flow reaching $55 million. Company ended the year with $181 million in cash, saw Joenja revenue surge 53% in Q4 and projected 2026 revenues of $405–425 million with gross margin at 90%.
| Metric | Value |
|---|---|
| Price | $12.95 |
| Market Cap | $891.29M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $21.34 |
| 52-Week Low | $7.31 |
| Volume | 2 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
3 analysts cover PHAR: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $38.00.